Volume: 12 Issue: 1
Year: 2024, Page: 12-18, Doi: https://doi.org/10.47799/pimr.1201.03
Received: Dec. 27, 2024 Accepted: Jan. 30, 2024 Published: Feb. 14, 2025
Background: Fungal infections (mucormycosis) have been reported as co-infection as well as opportunistic infection during and after COVID-19 (Coronavirus disease), involving the paranasal air sinuses with a high risk of morbidity and mortality. Considering the ongoing situation of COVID-19 associated with mucormycosis, we presented our experience of 110 patients being, or having previously been COVID -19 positive. Methods: This study included 110 patients in which surgical resection was done for Rhino-orbito-cerebral mucormycosis (ROCM) under general anesthesia and observed for 30 days postoperatively. Results: This study included 79 male patients with the majority of 51-60 years of age group (31.81%). Most common comorbidities observed in study were diabetes mellitus (77.27 %) followed by hypertension (39.09 %) & ischemic Heart Disease (9.09 %). Majority patients had received steroids (80 %) as a part of covid-19 treatment. All patients were receiving Amphotericin B at the time of surgery. On operative table extubation was possible in 80 % of the cases while others required average ICU stay (9.83 ± 7.33 days). Inotropic support was required in 20 % of patients. Majority patients were discharged successfully (85.45 %), while 10.91 % had mortality. On 30 days follow-up frontal Sinus Abscess (6.36 %) & maggots in maxilla and sphenoid (0.91 %) were noted. Conclusion: Corticosteroids and DM are the most important predisposing factors in the development of COVID-19-associated ROCM. Perioperative anesthesia care plays an important role towards management and outcome of ROC mucormycosis. Difficult intubation is anticipated due to fungal debris and supraglottic edema in the oropharynx of the patient.
Keywords: anesthesia management, COVID-19, mucormycosis, postoperative outcome, perioperative care
Singh, A K, Singh, R, Joshi, S R & Misra, A . 2021. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 15(4):102146.
Sen, M, Honavar, S G & Sharma, N . 2021. COVID-19 and eye: A review of ophthalmic manifestations of COVID-19. Indian J Ophthalmol 69(3):488–509.
Chakrabarti, A & Singh, R . 2014. Mucormycosis in India: unique features. Mycoses 57(3):85–90.
Jeong, W, Keighley, C & Wolfe, R . 2019. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect 25(1):26–34.
Cornely, O A, Alastruey-Izquierdo, A & Arenz, D . 2019. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 19(12):405–421.
Prakash, H & Chakrabarti, A . 2019. Global epidemiology of mucormycosis. J Fungi (Basel) 5(1):26.
Sharma, S, Grover, M, Bhargava, S, Samdani, S & Kataria, T . 2021. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 135(5):442–447.
Chander, J, Kaur, M, Singla, N, Punia, R, Singhal, S, Attri, A & Guarro, J . 2018. Mucormycosis: battle with the deadly enemy over a five-year period in India. J. Fungi 4(2):46.
Mishra, Y, Prashar, M & Sharma, D . 2021. Diabetes, COVID-19 and mucormycosis: clinical spectrum and outcome in a tertiary care medical centre in Western India. Diabet Metabol Syndr 15(4):102196.
Chakrabarti, A & Sood, P . 2013. Estimating fungal infection burden in India using computational models: mucormycosis burden as a case study. ECCMID .
Gupta, Ritesh, Kesavadev, Jothydev & Krisnan, Gopika . 2021. COVID-19 associated mucormycosis: A Descriptive Multisite Study from India. Diabetes & Metabolic Syndrome 15(6).
Sen, M, Honavar, S G & Bansal, R . 2021. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India-collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), report 1. Indian J. Ophthalmol 69(7):1670–1692.
Choksi, T, Agrawal, A & Date, P . 2021. Cumulative Mortality and Factors Associated with Outcomes of Mucormycosis After COVID-19 at a Multispecialty Tertiary Care Center in India. JAMA Ophthalmol 66–72.
Karaaslan, E . 2019. Anesthetic management of rhinoorbitocerebral mucormycosis; Focus on challenges. J Mycol Méd 29:219–241.
Kulkarni, P K, Reddy, N B, Shrinivas, B & Takkalki, V V . 2015. Anesthetic considerations in the management of mucormycosis. International Journal of Medicine and Public Health 5(4):387–390.
Jeong, S J, Lee, J U, Song, Y G, Lee, K H & Lee, M J . 2015. Delaying diagnostic procedures significantly increases mortality in patients with invasive mucormycosis. Mycoses 58(12):746–52.
©2024 (Ashwini Y Sontakke) et al. This is an open-access journal, and arƟcles are distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.
Sontakke AY, Kulkarni VV, Nandanvankar NN, Totawar S. Anesthesia Management of COVID-19 associated Rhino-Orbito-Cerebral Mucormycosis: A Prospective Observational Study. Perspectives in Medical Research. 2024;12(1):12-18 DOI: 10.47799/pimr.1201.03